PK, Safety,and Efficacy of Omacetaxine in Patients With Chronic Myeloid Leukemia
Study Title
- A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Teva Identifier
- C41443/2057 | 2013-005320-42
ClinicalTrials.gov Identifier
- NCT02078960
Study Status
- Terminated
Trial Condition(s)
- Chronic Myeloid Leukemia
Interventions
- Drug: Omacetaxine mepesuccinate
Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
Gender
- Female, Male
Age Range
- 18 Years and older
Trial Duration
- October 9, 2014 - November 27, 2017
Phase
- Phase 1/2
Study Type
Interventional
